Metabolism of drugs and other xenobiotics

Now, we come to offer you the right catalogues of book to open. metabolism of drugs and other xenobiotics is one of the literary work in this world in suitable to be reading material. That's not only this book gives reference, but also it will show you the amazing benefits of reading a book. Developing your countless minds is needed; moreover you are kind of people with great curiosity. So, the book is very appropriate for you.

[1]  M. Murray,et al.  Pharmacogenetics of phase I and phase II drug metabolism. , 2010, Current pharmaceutical design.

[2]  Yi Jin,et al.  Aldo-keto reductases and bioactivation/detoxication. , 2007, Annual review of pharmacology and toxicology.

[3]  Christian Montag,et al.  Investigating the genetic basis of altruism: the role of the COMT Val158Met polymorphism. , 2011, Social cognitive and affective neuroscience.

[4]  A. Seeringer,et al.  Clinical implications of pharmacogenetics of cytochrome P450 drug metabolizing enzymes. , 2007, Biochimica et biophysica acta.

[5]  M. Ranson,et al.  DT-diaphorase: a target for new anticancer drugs. , 2004, Cancer treatment reviews.

[6]  H. Schmidt,et al.  Comparative pharmacology of chemically distinct NADPH oxidase inhibitors , 2010, British journal of pharmacology.

[7]  Q. Cordeiro,et al.  Catechol-O-methyltransferase (COMT) val158met Polymorphism as a Risk Factor for PTSD After Urban Violence , 2011, Journal of Molecular Neuroscience.

[8]  Y. Kan,et al.  Induction of murine NAD(P)H:quinone oxidoreductase by 2,3,7,8-tetrachlorodibenzo-p-dioxin requires the CNC (cap 'n' collar) basic leucine zipper transcription factor Nrf2 (nuclear factor erythroid 2-related factor 2): cross-interaction between AhR (aryl hydrocarbon receptor) and Nrf2 signal transduc , 2004, The Biochemical journal.

[9]  Y. Sawada,et al.  Inhibitory effects of various beverages on human recombinant sulfotransferase isoforms SULT1A1 and SULT1A3 , 2007, Biopharmaceutics & drug disposition.

[10]  M. Ingelman-Sundberg,et al.  Cytochrome P450 proteins: retention and distribution from the endoplasmic reticulum. , 2010, Current opinion in drug discovery & development.

[11]  B. Zhu.  Catechol-O-Methyltransferase (COMT)-mediated methylation metabolism of endogenous bioactive catechols and modulation by endobiotics and xenobiotics: importance in pathophysiology and pathogenesis. , 2002, Current drug metabolism.

[12]  M. Manns,et al.  Developmental aspects of human hepatic drug glucuronidation in young children and adults , 2002, Gut.

[13]  T. Akabane,et al.  Case report of extensive metabolism by aldehyde oxidase in humans: Pharmacokinetics and metabolite profile of FK3453 in rats, dogs, and humans , 2011, Xenobiotica; the fate of foreign compounds in biological systems.

[14]  P. D. Josephy,et al.  Genetic Variations in Human Glutathione Transferase Enzymes: Significance for Pharmacology and Toxicology , 2010, Human genomics and proteomics : HGP.

[15]  M. Rashidi,et al.  Inhibitory effects of flavonoids on molybdenum hydroxylases activity , 2010, Expert opinion on drug metabolism & toxicology.

[16]  C. Wagner,et al.  Eukaryotic arylamine N-acetyltransferase. Investigation of substrate specificity by high-throughput screening. , 2005, Biochemical pharmacology.

[17]  L. Marnett,et al.  Co-oxygenation of organic substrates by the prostaglandin synthetase of sheep vesicular gland. , 1975, The Journal of biological chemistry.

[18]  T. Zhou,et al.  Sulfation of dietary flavonoids by human sulfotransferases , 2009, Xenobiotica; the fate of foreign compounds in biological systems.

[19]  Michael T. Green,et al.  Cytochrome P450 Compound I: Capture, Characterization, and C-H Bond Activation Kinetics , 2010, Science.

[20]  P. Valet,et al.  Alteration of amine oxidase activity in the adipose tissue of obese subjects. , 2004, Obesity research.

[21]  K. Reszka,et al.  Peroxidative metabolism of beta2-agonists salbutamol and fenoterol and their analogues. , 2009, Chemical research in toxicology.

[22]  J. Miners,et al.  The Novel UDP Glycosyltransferase 3A2: Cloning, Catalytic Properties, and Tissue Distribution , 2011, Molecular Pharmacology.

[23]  J. Cashman,et al.  Novel variants of the human flavin-containing monooxygenase 3 (FMO3) gene associated with trimethylaminuria. , 2009, Molecular genetics and metabolism.

[24]  R. Weinshilboum,et al.  Thiopurine S-methyltransferase pharmacogenetics: insights, challenges and future directions , 2006, Oncogene.

[25]  Neal L. Benowitz,et al.  Metabolism and Disposition Kinetics of Nicotine , 2005, Pharmacological Reviews.

[26]  G. Schneider,et al.  Crystal structure of dihydropyrimidine dehydrogenase, a major determinant of the pharmacokinetics of the anti‐cancer drug 5‐fluorouracil , 2001, The EMBO journal.

[27]  R. T. Williams.  Detoxication mechanisms : the metabolism and detoxication of drugs, toxic substances and other organic compounds , 1959 .

[28]  J. Uetrecht,et al.  Metabolism of ticlopidine by activated neutrophils: implications for ticlopidine-induced agranulocytosis. , 2000, Drug metabolism and disposition: the biological fate of chemicals.

[29]  E. Maser,et al.  Carbonyl Reductases and Pluripotent Hydroxysteroid Dehydrogenases of the Short-chain Dehydrogenase/reductase Superfamily , 2007, Drug metabolism reviews.

[30]  K. Knights,et al.  Amino acid conjugation: contribution to the metabolism and toxicity of xenobiotic carboxylic acids , 2007, Expert opinion on drug metabolism & toxicology.

[31]  L. Aarons,et al.  Phase I pharmacokinetic and pharmacodynamic study of the bioreductive drug RH1. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

[32]  M. Manns,et al.  Coffee induces expression of glucuronosyltransferases by the aryl hydrocarbon receptor and Nrf2 in liver and stomach. , 2010, Gastroenterology.

[33]  P. Anzenbacher,et al.  Phase II drug metabolizing enzymes. , 2010, Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia.

[34]  J. Guss,et al.  Correlation of active site metal content in human diamine oxidase with trihydroxyphenylalanine quinone cofactor biogenesis . , 2010, Biochemistry.

[35]  W. Poewe,et al.  Acute double-blind, placebo-controlled sleep laboratory and clinical follow-up studies with a combination treatment of rr-L-dopa and sr-L-dopa in restless legs syndrome , 2003, Journal of Neural Transmission.

[36]  N. Vermeulen,et al.  Genetic polymorphisms of human N-acetyltransferase, cytochrome P450, glutathione-S-transferase, and epoxide hydrolase enzymes: relevance to xenobiotic metabolism and toxicity. , 1999, Critical reviews in toxicology.

[37]  A. Kalgutkar,et al.  Assessment of the contributions of CYP3A4 and CYP3A5 in the metabolism of the antipsychotic agent haloperidol to its potentially neurotoxic pyridinium metabolite and effect of antidepressants on the bioactivation pathway. , 2003, Drug metabolism and disposition: the biological fate of chemicals.

[38]  R. Weinshilboum,et al.  Human estrogen sulfotransferase gene (STE): cloning, structure, and chromosomal localization. , 1995, Genomics.

[39]  R. Weinshilboum,et al.  Human liver dehydroepiandrosterone sulfotransferase: molecular cloning and expression of cDNA. , 1992, Molecular pharmacology.

[40]  K. Krause,et al.  The NOX family of ROS-generating NADPH oxidases: physiology and pathophysiology. , 2007, Physiological reviews.

[41]  Jackie C Bloomer,et al.  Quantitative Evaluation of the Expression and Activity of Five Major Sulfotransferases (SULTs) in Human Tissues: The SULT “Pie” , 2009, Drug Metabolism and Disposition.

[42]  P. Beaune,et al.  Human cytochromes P450 , 1999 .

[43]  P. Workman,et al.  DT-diaphorase and cancer chemotherapy. , 1992, Biochemical pharmacology.

[44]  G. Pacifici.  Inhibition of human liver and duodenum sulfotransferases by drugs and dietary chemicals: a review of the literature. , 2004, International journal of clinical pharmacology and therapeutics.

[45]  E. Maser,et al.  Development of daunorubicin resistance in tumour cells by induction of carbonyl reduction. , 2000, Biochemical pharmacology.

[46]  D. Spitz,et al.  Inactivation of anthracyclines by cellular peroxidase. , 2005, Cancer research.

[47]  David E. Williams,et al.  Flavin-containing monooxygenase-3: induction by 3-methylcholanthrene and complex regulation by xenobiotic chemicals in hepatoma cells and mouse liver. , 2010, Toxicology and applied pharmacology.

[48]  I. Phillips,et al.  Flavin-containing monooxygenases: mutations, disease and drug response. , 2008, Trends in pharmacological sciences.

[49]  Tony K L Kiang,et al.  UDP-glucuronosyltransferases and clinical drug-drug interactions. , 2005, Pharmacology & therapeutics.

[50]  J. Miners,et al.  Quantitative prediction of in vivo inhibitory interactions involving glucuronidated drugs from in vitro data: the effect of fluconazole on zidovudine glucuronidation. , 2006, British journal of clinical pharmacology.

[51]  M. S. Ching,et al.  Fetal hepatic drug elimination. , 1999, Pharmacology & therapeutics.

[52]  Gerald T Miwa,et al.  Bioactivation of drugs: risk and drug design. , 2011, Annual review of pharmacology and toxicology.

[53]  A. Oakley.  Glutathione transferases: a structural perspective , 2011, Drug metabolism reviews.

[54]  S. Vuilleumier,et al.  Conjugation of haloalkanes by bacterial and mammalian glutathione transferases: mono- and dihalomethanes. , 2001, Chemical research in toxicology.

[55]  M. Noble,et al.  An update on genetic, structural and functional studies of arylamine N-acetyltransferases in eucaryotes and procaryotes. , 2000, Human molecular genetics.

[56]  P. Neuvonen,et al.  Mechanism‐Based Inactivation of CYP2C8 by Gemfibrozil Occurs Rapidly in Humans , 2011, Clinical pharmacology and therapeutics.

[57]  R. Gearry,et al.  Allopurinol-thiopurine combination therapy in inflammatory bowel disease: are there genetic clues to this puzzle? , 2010, Pharmacogenomics.

[58]  C. Guillemette,et al.  Nomenclature update for the mammalian UDP glycosyltransferase (UGT) gene superfamily. , 2005, Pharmacogenetics and genomics.

[59]  P. de Miranda,et al.  6-Deoxyacyclovir: a xanthine oxidase-activated prodrug of acyclovir. , 1984, Proceedings of the National Academy of Sciences of the United States of America.

[60]  B. Tang,et al.  Variable activation of lovastatin by hydrolytic enzymes in human plasma and liver , 2004, European Journal of Clinical Pharmacology.

[61]  J. Uetrecht,et al.  Clozapine is oxidized by activated human neutrophils to a reactive nitrenium ion that irreversibly binds to the cells. , 1995, The Journal of pharmacology and experimental therapeutics.

[62]  C. Obinger,et al.  Active site structure and catalytic mechanisms of human peroxidases. , 2006, Archives of biochemistry and biophysics.

[63]  P. Dostert,et al.  Contribution of amine oxidases to the metabolism of xenobiotics. , 1994, Drug metabolism reviews.

[64]  Richard M. Weinshilboum,et al.  Pharmacogenomics: Catechol O-Methyltransferase to Thiopurine S-Methyltransferase , 2006, Cellular and Molecular Neurobiology.

[65]  J. Miners,et al.  SELECTIVITY OF SUBSTRATE (TRIFLUOPERAZINE) AND INHIBITOR (AMITRIPTYLINE, ANDROSTERONE, CANRENOIC ACID, HECOGENIN, PHENYLBUTAZONE, QUINIDINE, QUININE, AND SULFINPYRAZONE) “PROBES” FOR HUMAN UDP-GLUCURONOSYLTRANSFERASES , 2006, Drug Metabolism and Disposition.

[66]  J. Uetrecht.  Idiosyncratic drug reactions: past, present, and future. , 2008, Chemical research in toxicology.

[67]  M. Benedetti.  FAD-dependent enzymes involved in the metabolic oxidation of xenobiotics , 2011 .

[68]  M. Boroujerdi,et al.  Biotransformation of Xenobiotics , 2015 .

[69]  M. B. Kovacic,et al.  Airway Peroxidases Catalyze Nitration of the β2-Agonist Salbutamol and Decrease Its Pharmacological Activity , 2011, Journal of Pharmacology and Experimental Therapeutics.

[70]  Y. Sugiyama,et al.  Prediction of in vivo drug-drug interactions based on mechanism-based inhibition from in vitro data: inhibition of 5-fluorouracil metabolism by (E)-5-(2-Bromovinyl)uracil. , 2000, Drug metabolism and disposition: the biological fate of chemicals.

[71]  K. H. Lee,et al.  Suppression of flavin-containing monooxygenase by overproduced nitric oxide in rat liver. , 1999, Molecular pharmacology.

[72]  X. Wu,et al.  Side-chain metabolism of propranolol: involvement of monoamine oxidase and aldehyde reductase in the metabolism of N-desisopropylpropranolol to propranolol glycol in rat liver. , 2001, Comparative biochemistry and physiology. Toxicology & pharmacology : CBP.

[73]  C. Falany,et al.  Characterization of expressed human phenol-sulfating phenol sulfotransferase: effect of mutating cys70 on activity and thermostability. , 1994, Chemico-biological interactions.

[74]  A. Rettie,et al.  Transformation Enzymes: Oxidative; Non-P450 , 1999 .

[75]  R. Egan,et al.  Acetaminophen and analogs as cosubstrates and inhibitors of prostaglandin H synthase. , 1988, Chemico-biological interactions.

[76]  M. Becker,et al.  Selectivity of febuxostat, a novel non-purine inhibitor of xanthine oxidase/xanthine dehydrogenase. , 2005, Life sciences.

[77]  D. Grant,et al.  Monomorphic and polymorphic human arylamine N-acetyltransferases: a comparison of liver isozymes and expressed products of two cloned genes. , 1991, Molecular pharmacology.

[78]  J. Kehrer,et al.  Cooxidation of cyclophosphamide as an alternative pathway for its bioactivation and lung toxicity. , 1991, Cancer research.

[79]  J. Miners,et al.  “Phase I and Phase II” Drug Metabolism: Terminology that we Should Phase Out? , 2005, Drug metabolism reviews.

[80]  Mei Li,et al.  Crystal structure of human sulfotransferase SULT1A3 in complex with dopamine and 3'-phosphoadenosine 5'-phosphate. , 2005, Biochemical and biophysical research communications.